...
首页> 外文期刊>American Journal of Epidemiology >Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration
【24h】

Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration

机译:用药物浓度阈值评估参与者的暴露前预防预防HIV的功效

获取原文
获取原文并翻译 | 示例
           

摘要

Assays for detecting levels of antiretroviral drugs in study participants are increasingly popular in preexposure prophylaxis (PrEP) trials, since they provide an objective measure of adherence. Current correlation analyses of drug concentration data are prone to bias. In this article, we formulate the causal estimand of prevention efficacy among drug compliers, those who would have had a threshold level of drug concentration had they been assigned to the drug arm of the trial. The identifiability of the causal estimand is facilitated by exploiting the exclusion restriction; that is, drug noncompliers do not acquire any prevention benefit. In addition, we develop an approach to sensitivity analysis that relaxes the exclusion restriction. Applications to published data from 2 PrEP trials, namely the Preexposure Prophylaxis Initiative (iPrEx) trial and the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial, suggest high efficacy estimates among drug compliers (in the iPrEx trial, odds ratio = 0.097 (95% confidence interval: 0.027, 0.352); in the CAPRISA 004 trial, odds ratio = 0.104 (95% confidence interval: 0.024, 0.447)). In summary, the proposed inferential method provides an unbiased assessment of PrEP efficacy among drug compliers, thus adding to the primary intention-to-treat analysis and correlation analyses of drug concentration data.
机译:在研究对象中检测抗逆转录病毒药物水平的方法在暴露前预防(PrEP)试验中越来越受欢迎,因为它们提供了客观的依从性度量。当前药物浓度数据的相关性分析容易产生偏差。在本文中,我们制定了药物编写者之间预防效果的因果关系估计值,如果将其分配给试验的药物部门,他们本应具有阈值的药物浓度。利用排除限制可促进因果估计的可识别性;也就是说,不遵守药物规定的人不会获得任何预防益处。此外,我们开发了一种敏感性分析方法,可以放宽排除限制。来自2个PrEP试验的公开数据的申请,即暴露前预防倡议(iPrEx)试验和南非艾滋病研究中心(CAPRISA)004试验,表明药物编写者中的高疗效估计值(在iPrEx试验中,几率比率= 0.097(95%置信区间:0.027,0.352);在CAPRISA 004试验中,优势比= 0.104(95%置信区间:0.024,0.447)。总而言之,所提出的推论方法在药物编写者之间提供了对PrEP功效的公正评估,从而增加了药物浓度数据的主要意向治疗分析和相关性分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号